PhRMA Urges Japan To Create Separate Regulations For Biosimilars
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The Pharmaceutical Research and Manufacturers of America called on Japan to create a separate regulatory structure for biosimilar drugs from branded biologics, a day after the Ministry of Health, Labor and Welfare released a draft biosimilar guideline Sept. 17
You may also be interested in...
Sandoz's Somatropin Becomes First Biosimilar Approved In Japan
Japan's Ministry of Health, Labor and Welfare approved the recombinant human growth hormone injection less than a year after releasing draft guidelines and three months after Sandoz/Novartis submitted the application.
Sandoz's Somatropin Becomes First Biosimilar Approved In Japan
Japan's Ministry of Health, Labor and Welfare approved the recombinant human growth hormone injection less than a year after releasing draft guidelines and three months after Sandoz/Novartis submitted the application.
Japan Chemical Research, Kissei Submit First Biosimilar Application In Japan
TOKYO - Japan Chemical Research Pharmaceutical of Kobe in Western Japan and Kissei Pharmaceutical of Matsumoto City in central Japan have applied to the Ministry of Health, Labor and Welfare for marketing what is expected to be Japan's first biosimilar therapeutic, spokespersons for the two companies told PharmAsia News Nov. 26